Monday, May 23, 2011

Provenge - Is Medicare Encouraging 'No Cost Is Too Much' Attitude? - CNBC

The cutting-edge technology has no significant side effects, but also happens to have almost no measurable effects of any kind: Tumors don’t shrink. Blood tests are unchanged. But men with otherwise intractable prostate cancer who get the procedure tend to live a bit longer —4.1 months is the median.

And it’s very, very expensive — about $93,000 for a course of treatment.

Posted via email from Jack's posterous

No comments: